Unanswered Questions Around PD98059 Published

This showed close agreement between the published data and our experiments, where five are proliferative signature lines http://www.selleckchem.com/products/Rapamycin.html (888mel, WM983A, WM983B, 501mel and SK-MEL-28) and three are invasive signature lines (WM793B, WM852 and 1205Lu). Then, we assessed their in vitro proliferative and invasive characteristics. We found for these cell lines that while there was no significant difference in population doubling times between proliferative (34.1?h) and invasive (34.7?h) signature lines (Figure?2D), there was a significant difference (P? http://www.selleckchem.com/products/Everolimus(RAD001).html phenotype signatures. Four different data sets (GSE10916, GSE4841, GSE4843 and GSE7127) supply genotyping information concerning the mutation status of BRAF. HOPP analyses of these show there is no significant association between the HOPP result and BRAF mutation status (Figure?3). This indicates that BRAF mutation status has no relationship with phenotype-specific gene expression. In vitro, melanoma cell phenotype is assumed to be relatively homogenous and it is supposed that nearly all cells in a given culture share a uniform level of gene expression. In contrast to this, in vivo observation of melanoma tumours reveals a heterogeneous distribution of many markers as tumours typically include an irregularly distributed composition http://www.selleck.cn/products/PD-98059.html of tumour, stromal and infiltrating immune cells. The distribution of marker genes specific to invasive or proliferative phenotypes suggests that tumours, and the biopsies taken from them, also include cells of both phenotypes in proportions which are difficult to predict. Subsequently, while the measurement of the expression of any given gene is its mean among all cells in a biopsy, it does not necessarily follow that this is representative of the entire lesion. Thus, tumour heterogeneity, with its irregular distribution of cell phenotypes, likely complicates the drawing of clinically relevant conclusions from expression data obtained from either biopsies or derived cell cultures.